Director of Analysis EpiVax, Inc. Providence, Rhode Island
The potential for immunogenicity and anti-drug antibody (ADA) generation is a hurdle that drug developers face in the process of bringing biologics innovations to the clinic. At the same time, new biologics formats have enabled developers to engineer products with improved function and specificity. The creation of an integrated in silico screening and re-engineering platform called ISPRI has made it possible to rapidly assess the overall immunogenic potential of a biologic and to identify individual T cell epitope clusters that may contribute to immunogenicity in the clinical setting. Here we present several examples of the ISPRI-driven assessment of novel format biologics such as fusion proteins, bispecific antibodies and antibody-drug conjugates.
Learning Objectives:
Understand the T-cell contribution to anti-therapeutic antibody response.
Learn in silico approaches to predict T cell response and their correlation with anti-therapeutic response in the clinic.
Use ISPRI to assess immunogenic potential of three proteins with distinct formats and functions and compare results to clinical observations.
